Vaccinex, Inc. (OTCPK: VCNX)
Health Care · Biotechnology · US
$1.10
+32.10% today · +139.1% 1Y
Vaccinex, Inc. (OTCPK: VCNX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.94M and employs 25 people.
Over the last twelve months the share price has gained 139.1%, trading between 0.31 and 1.50.
Tweenvest scores Vaccinex, Inc. across four factors: quality 15/100, value 51/100. Its strongest factor is value.
VCNX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.94M
- Revenue (TTM)
- $601.00K
- P/E
- —
- EPS
- -8.88
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- $1.50
- 52-week low
- $0.31
- Avg volume (3M)
- —
- Shares outstanding
- 2.68M
- Employees
- 25
- Next earnings
- —
About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
- ISIN
- US9186403013
- Founded
- 2001
- Listed since
- Aug 9, 2018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.31 | +0.51% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.